文献速递消化道肿瘤放疗姑息放疗与转移瘤

大分割放化疗在食管癌及胃食管结合部癌姑息治疗中的I期试验

Phase I trial of hypofractionated chemoradiotherapy in the palliative management of esophageal and gastro-esophageal cancer.
PubMed 文献 · Radiat Oncol · 2022-09-14

这项I期试验纳入18例有吞咽困难的食管或胃食管结合部鳞癌或腺癌患者,采用四个逐步缩短的放疗日程(最终为30 Gy/10次)联合同期每周卡铂AUC 2和紫杉醇50 mg/m²化疗。试验中未出现剂量限制性毒性(食管穿孔或发热性中性粒细胞减少),所有患者吞咽困难均改善,中位改善时间3周,中位无吞咽困难进展生存5.8个月,中位总生存8.9个月。

要点

  • 30 Gy/10次大分割姑息放化疗联合同期每周卡铂和紫杉醇未出现剂量限制性毒性。
  • 所有患者吞咽困难均改善,中位改善时间3周(范围2-10周)。
  • 中位无吞咽困难进展生存5.8个月,中位总生存8.9个月。

核心结论

  • 30 Gy/10次大分割姑息放化疗联合同期每周卡铂和紫杉醇耐受良好,并在改善吞咽困难方面提供良好反应。
  • 作者认为需进一步开展研究,既改善原发肿瘤症状又控制转移负荷。

研究设计与样本

  • I期试验,纳入18例组织学证实的食管或胃食管结合部鳞癌或腺癌伴局部病变所致症状性吞咽困难且不适合根治性治疗的患者。
  • 患者需年龄18岁及以上、ECOG体能状态0-2分且适合接受卡铂和紫杉醇化疗。
  • 患者按逐步方式进入四个逐步缩短的放疗日程,最终为30 Gy分10次,均联合同期每周卡铂AUC 2和紫杉醇50 mg/m²化疗。
  • 主要终点为剂量限制性毒性(食管穿孔或发热性中性粒细胞减少)的发生,次要终点包括吞咽困难缓解、吞咽困难改善时间、无吞咽困难进展生存和总生存。
  • 试验于2014年10月至2019年3月入组患者,前瞻性注册于www.anzctr.org.au,注册号ACTRN12614000821695。

主要发现

  • 试验期间未出现剂量限制性毒性。
  • 最常见的3级及以上急性毒性为恶心和呕吐(均为4/18例患者)。
  • 最常见的放疗特异性急性毒性为食管炎,67%的患者出现1-2级症状。
  • 所有患者吞咽困难均改善,中位改善时间为放化疗开始后3周(范围2-10周)。
  • 中位无吞咽困难进展生存为5.8个月,中位总生存为8.9个月。

关键数值与推荐

  • 放疗日程为四个逐步缩短的方案,最终为30 Gy分10次。
  • 同期化疗为每周卡铂AUC 2和紫杉醇50 mg/m²,与放疗同期进行。
  • 主要终点剂量限制性毒性定义为食管穿孔或发热性中性粒细胞减少。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为需进一步开展研究,既提供原发肿瘤的症状改善又控制转移负荷。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many patients with incurable esophageal cancer (ECa) present with dysphagia as their predominant symptom. Currently there is no consensus on how best to initially manage this scenario with multiple therapeutic options available. We aimed to assess the safety and efficacy of using hypofractionated radiotherapy given over a progressively shorter timeframe with concurrent carboplatin and paclitaxel in the management of patients with ECa and dysphagia. METHODS: In this phase I trial we enrolled patients with histologically proven squamous cell carcinoma or adenocarcinoma of the esophagus or the gastro-esophageal junction with symptomatic dysphagia from local disease and not for curative treatment. Patients needed to be 18 years or older, have an ECOG performance status of 0-2 and be suitable to receive carboplatin and paclitaxel chemotherapy. Patients were placed in four progressively shorter radiation schedules culminating in 30 Gy in 10 fractions in a step wise manner, all with concurrent carboplatin AUC 2 and paclitaxel 50 mg/m2 chemotherapy delivered weekly with the radiation therapy. The primary endpoint was the development of the dose limiting toxicities (DLTs) esophageal perforation or febrile neutropenia. Secondary endpoints were relief of dysphagia, time to improvement of dysphagia, dysphagia progression free survival and overall survival. RESULTS: Eighteen patients were enrolled in the study between October 2014 and March 2019. There were no DLTs experienced during the trial. The most common grade 3 + acute toxicity experienced by patients were nausea and vomiting (both in 4/18 patients). The most common radiation specific acute toxicity experienced was esophagitis with 67% of patients experiencing grade 1-2 symptoms. All patients experienced improvement in dysphagia. The median time to dysphagia improvement was 3 weeks from the start of chemoradiotherapy (CTRT) (range 2-10 weeks). The median dysphagia free survival was 5.8 months with a median overall survival of 8.9 months. CONCLUSION: Hypofractionated palliative CTRT with 30 Gy/10# of radiation therapy with concurrent weekly carboplatin and paclitaxel chemotherapy is well tolerated and provides a good response in improvement of dysphagia. Further studies need to be undertaken which provide both symptomatic improvement in the primary tumor but also control of the metastatic burden in these patients. CLINICAL TRIAL REGISTRATION: This trial was prospectively registered with www.anzctr.org.au Identifier: ACTRN12614000821695.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Sridharan S, Day F, Loh J, et al. Phase I trial of hypofractionated chemoradiotherapy in the palliative management of esophageal and gastro-esophageal cancer. Radiat Oncol. 2022. PMID: 36104707. doi:10.1186/s13014-022-02127-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。